Similar Stories to Alexion Pays Hefty $8.4 Billion To Acquire Synageva, Expand Rare Disease Drug Business on Bing News

CHESHIRE, Conn. (TheStreet) -- Alexion Pharmaceuticals is buying Synageva Biopharma for $8.4 billion to broaden its offering of treatments for rare diseases, the companies announced Wednesday. The cash and stock deal values Synageva at $230 per share, based on Alexion's average closing price for the past nine days. That's a 140% premium to Synageva's closing price of $95.87 on Tuesday. Alexion is already one of the most successful marketers of so-called "ultra orphan drugs" -- treatments for rare, genetic diseases which carry gigantic price tags.

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News